

Resource Summary Report

Generated by [NIF](#) on Aug 10, 2026

Ramos

RRID:CVCL_0597

Type: Cell Line

Proper Citation

RRID:CVCL_0597

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0597

Proper Citation: RRID:CVCL_0597

Description: Cell line Ramos is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Burkitt lymphoma

Defining Citation: [PMID:62724](#), [PMID:175026](#), [PMID:181343](#), [PMID:1850347](#), [PMID:1915267](#), [PMID:2052620](#), [PMID:2835030](#), [PMID:2985879](#), [PMID:2998993](#), [PMID:3026973](#), [PMID:3159941](#), [PMID:3518877](#), [PMID:3874327](#), [PMID:6231253](#), [PMID:6286763](#), [PMID:7316467](#), [PMID:7757991](#), [PMID:8316623](#), [PMID:8344493](#), [PMID:8402660](#), [PMID:8515068](#), [PMID:8896424](#), [PMID:9192833](#), [PMID:9225077](#), [PMID:9473234](#), [PMID:9563901](#), [PMID:9973220](#), [PMID:10739008](#), [PMID:10918597](#), [PMID:11226526](#), [PMID:12967475](#), [PMID:18211290](#), [PMID:20922763](#), [PMID:22885699](#), [PMID:24590883](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:31160637](#)

Comments: Virology: EBV-negative., Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Ramos

Synonyms: RAMOS, Ramos 1, RA 1, RA.1, Ra #1, Ra No. 1, Ramos(RA1), Ramos-RA1, Ramos (RA 1), Ramos (RA #1), Ramos (RA)

Cross References: BTO:BTO_0003079, CLO:CLO_0008738, CLO:CLO_0008739, EFO:EFO_0002077, MCCL:MCC:0000410, CLDB:cl4096, CLDB:cl4097, CLDB:cl4098, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-1596, BCRC:60252, BEI_Resources:ARP-9938, BioGRID_ORCS_Cell_line:151, BioSample:SAMN01821590, BioSample:SAMN01821657, BioSample:SAMN03472718, cancercellines:CVCL_0597, CCRID:1101HUM-PUMC000048, CCRID:1102HUM-NIFDC00052, Cell_Model_Passport:SIDM01094, CGH-DB:9205-4, ChEMBL-Cells:ChEMBL3307664, ChEMBL-Targets:ChEMBL614629, CLS:302007, Cosmic:929817, Cosmic:931111, Cosmic:991547, Cosmic:998719, Cosmic:1037704, Cosmic:1226864, Cosmic:1509204, Cosmic:1517660, Cosmic:1762459, Cosmic:1818347, Cosmic:2750875, Cosmic:2759408, Cosmic:2814542, Cosmic:2823075, DepMap:ACH-001636, DSMZ:ACC-603, DSMZCellDive:ACC-603, ECACC:85030802, ECACC:91030710, EGA:EGAS00001000610, FCS-free:243-2-490-3-4-12, GEO:GSM99388, GEO:GSM987747, GEO:GSM987748, GEO:GSM987749, GEO:GSM1374843, GEO:GSM1374844, GEO:GSM3150254, IARC_TP53:180, JCRB:JCRB9119, KCLB:21596, LINCS_HMS:50811, LINCS_LDP:LCL-1097, Lonza:725, NCBI_Iran:C128, PharmacDB:RAMOS_1283_2019, PRIDE:PXD000447, PRIDE:PXD012087, PubChem_Cell_line:CVCL_0597, Wikidata:Q54949198

ID: CVCL_0597

Record Creation Time: 20220427T221450+0000

Record Last Update: 20260809T002642+0000

Ratings and Alerts

No rating or validation information has been found for Ramos.

No alerts have been found for Ramos.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 1013 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cheng Y, et al. (2026) A 3D genome atlas of human tonsil and the role of loop extrusion in B cell somatic hypermutation. Science (New York, N.Y.), 393(6809), eadw4243.

de Blas A, et al. (2026) Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. Cancer research, 86(12), 2896.

Wang L, et al. (2026) A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. *Journal of hematology & oncology*, 19(1).

Opassi G, et al. (2026) Identification of a Shiga toxin A-derived peptide internalized into Gb3 receptor-bearing cells via interaction with the Shiga toxin B subunit. *FEBS letters*.

Luo S, et al. (2025) TCL1A in na^{ve} B cells as a therapeutic target for type 1 diabetes. *EBioMedicine*, 113, 105593.

Lin AY, et al. (2025) Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML. *Blood neoplasia*, 2(4), 100122.

Thomas BJ, et al. (2025) DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. *Cancer immunology research*, 13(11), 1798.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Probst P, et al. (2025) Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. *Molecular cancer therapeutics*, 24(6), 803.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. *Molecular cell*, 85(13), 2597.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.

Pizzo ME, et al. (2025) Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. *Science (New York, N.Y.)*, 389(6760), eads3204.

Eisen TJ, et al. (2025) Conditional requirement for dimerization of the membrane-binding module for BTK signaling in lymphocyte cell lines. *Science signaling*, 18(869), eado1252.

Jeong Y, et al. (2025) Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. *Frontiers in immunology*, 16, 1578665.

Chen P, et al. (2025) Assessment of the Effects of Single-Domain Anti-Idiotypic Distribution Enhancers on the Disposition of Trastuzumab and on the Efficacy of a PE24-Trastuzumab Immunotoxin. *Cancers*, 17(9).

Granda Farias A, et al. (2025) Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity. *Cell reports*, 44(7), 115921.

Sindram E, et al. (2025) LRBA deficiency impairs autophagy and contributes to enhanced antigen presentation and T-cell dysregulation. *EMBO reports*, 26(16), 4040.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

Li W, et al. (2024) Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. *Molecular cancer*

therapeutics, 23(1), 35.

Chen Y, et al. (2024) Functionalized tetrahedral DNA frameworks for the capture of circulating tumor cells. Nature protocols.